BioNTech SE (BNTX) Yield on Cost (YOC): 2.44%
The yield on cost (YOC) for BioNTech SE (BNTX) is 2.44%.
BNTX Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
2.44%
Forward Yield on Cost Projections
If you buy BNTX today at the current stock price of $86.50 with a yield of 2.44% and dividends continue to grow at the historical rate (8.0% CAGR), your YOC would be:
Current Yield
2.44%
YOC in 3 Years
N/A
YOC in 5 Years
N/A
YOC in 10 Years
N/A
Interactive Yield on Cost Calculator
Project custom investment returns for BioNTech SE (BNTX) based on your custom cost basis.
Starting Yield
2.44%
Ending YOC
7.74%
Year 15 Dividend
$6.69
Cum. Dividends Recd.
$61.87
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $2.11 | — | 2.44% | $0.00 |
| Year 1 | $2.28 | +8.00% | 2.63% | $2.28 |
| Year 2 | $2.46 | +8.00% | 2.85% | $4.74 |
| Year 3 | $2.66 | +8.00% | 3.07% | $7.40 |
| Year 4 | $2.87 | +8.00% | 3.32% | $10.27 |
| Year 5 | $3.10 | +8.00% | 3.58% | $13.37 |
| Year 6 | $3.35 | +8.00% | 3.87% | $16.72 |
| Year 7 | $3.62 | +8.00% | 4.18% | $20.33 |
| Year 8 | $3.91 | +8.00% | 4.51% | $24.24 |
| Year 9 | $4.22 | +8.00% | 4.88% | $28.46 |
| Year 10 | $4.56 | +8.00% | 5.27% | $33.01 |
| Year 11 | $4.92 | +8.00% | 5.69% | $37.93 |
| Year 12 | $5.31 | +8.00% | 6.14% | $43.25 |
| Year 13 | $5.74 | +8.00% | 6.63% | $48.98 |
| Year 14 | $6.20 | +8.00% | 7.16% | $55.18 |
| Year 15 | $6.69 | +8.00% | 7.74% | $61.87 |
Yield on Cost (YOC) Formula
Formula: Yield on Cost = Annual Dividend / Original Purchase Price × 100
Inputs shown in the projection:
- Original purchase price.
- Annual dividend per share at the starting point.
- Assumed annual dividend growth rate.
- Projected annual dividend divided by original purchase price.
Note: Forward projections assume dividends continue to grow at the designated growth rate. Actual dividend payments are declared by corporate boards and are subject to change.
BioNTech SE Yield on Cost (YOC) Formula & Definition
Yield on Cost shows the dividend yield based on your original purchase price. As dividends grow, your YOC increases even if the market yield stays the same.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
BioNTech SE Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for BioNTech SE (BNTX)?
- The yield on cost (YOC) for BNTX stock is 2.44%.
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin